Having trouble viewing this email? View it as a Web page. Change in PDL Status for Intranasal Rhinitis Agents Drug Class, Effective Sept. 29, 2025 Texas Medicaid removed the non-preferred status for certain generic azelastine/fluticasone nasal products on the Texas Preferred Drug List following a drug shortage on brand Dymista products. Other News Columbus Day Holiday to Delay Pharmacy Payments HHSC to Participate in Cell and Gene Therapy Access Model Temporary Non-preferred Drug Status Begins Sept. 1, 2025 Outreach and Training Reminders Pharmacies Must Ensure Contact Information Is Current in PEMS Drug Shortage and Expedited Formulary, Preferred Drug List Addition Notification Available Texas Health Steps Includes Pharmacy Education Opportunities

---

You have subscribed to get updates about Texas Health and Human Services (HHS). For more information about HHS, please visit our website.

---

Stay Connected
					(en español)

Subscriber Services
Manage Preferences  |  Unsubscribe  |  Help

This email was sent to stevenmagallanes520.nims@blogger.com using govDelivery Communications Cloud on behalf of: Texas Health and Human Services Commission · 707 17th St, Suite 4000 · Denver, CO 80202